Literature DB >> 33275738

Monoclonal gammopathies of clinical significance.

Angela Dispenzieri1.   

Abstract

"Monoclonal gammopathy of clinical significance" (MGCS) is the term used to describe nonmalignant monoclonal gammopathies causing important disease. MGCS is the differential diagnosis for any patient presenting with what appears to be a monoclonal gammopathy of undetermined significance but is also experiencing other unexplained symptoms. Broadly, these conditions can be separated into symptoms and signs referable to the nerves, the kidneys, and the skin. The first step in making these diagnoses is to consider them. With a particular condition in mind, the next step is to order those tests that can help confirm or dismiss a particular diagnosis. Nearly all of the renal and dermatologic conditions are diagnosed by renal and skin biopsies, respectively. The importance of a highly competent renal pathologist and dermatopathologist cannot be underestimated. Biopsy is less specific for the neuropathic conditions. Because several of the MGCSs are syndromes, recognizing other manifestations is also key. Treatment recommendations for many of these conditions are anecdotal because of their rarity, but for several of the conditions, IV immunoglobulin, rituximab, and plasma cell-directed therapy are the best options.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33275738      PMCID: PMC7727544          DOI: 10.1182/hematology.2020000122

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  43 in total

Review 1.  Systemic immunoglobulin light chain amyloidosis.

Authors:  Giampaolo Merlini; Angela Dispenzieri; Vaishali Sanchorawala; Stefan O Schönland; Giovanni Palladini; Philip N Hawkins; Morie A Gertz
Journal:  Nat Rev Dis Primers       Date:  2018-10-25       Impact factor: 52.329

2.  Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.

Authors:  Thibault Mahévas; Bertrand Arnulf; Jean-David Bouaziz; Cristina Bulai Livideanu; Amélie Osio; Amandine Servy; Bernard Cribier; Bruno Sassolas; Marie Jachiet; Laurence Michel; Pierre Aucouturier; Dan Lipsker; Camille Frances; Emilie Sbidian; Michel Rybojad; Vincent Descamps; Michel D'Incan; Philippe Humbert; Marie Beylot-Barry; Thierry Passeron; Claire de Moreuil; Ruba Y Taha; Olivier Hermine; Alain Dupuy; Sébastien Barbarot; Sébastien Debarbieux; Olivier Carpentier; Fanny Brault; Jean-Luc Schmutz; Domitille Thomas-Beaulieu; Philippe Modiano; Charles Zarnitsky; François Lifermann; Emilie Baubion; Nicolas Limal; Fabien Le Bras; Marie Le Moigne; Marie Tauber; Alexis Talbot; Romain Prud'homme; Sandy Peltier; Adèle De Masson; Maxime Battistella; Martine Bagot; Arsène Mékinian; Olivier Fain
Journal:  Blood       Date:  2020-04-02       Impact factor: 22.113

Review 3.  Cutis laxa associated with monoclonal gammopathy: 14 new cases and review of the literature.

Authors:  Marie Jachiet; Stéphanie Harel; Anne Saussine; Maxime Battistella; Michel Rybojad; Bouchra Asli; Djaouida Bengoufa; Thibault Mahevas; Didier Bessis; Lionel Galicier; Jean-Luc Schmutz; Smail Hadj-Rabia; David Boutboul; Céleste Lebbé; Martine Bagot; Marion Malphettes; Dan Lipsker; Jean-Paul Fermand; Jean-David Bouaziz; Bertrand Arnulf
Journal:  J Am Acad Dermatol       Date:  2018-04-03       Impact factor: 11.527

4.  Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome.

Authors:  Dorota M Rowczenio; Shelly Pathak; Juan I Arostegui; Anna Mensa-Vilaro; Ebun Omoyinmi; Paul Brogan; Dan Lipsker; Thomas Scambler; Roger Owen; Hadija Trojer; Anna Baginska; Julian D Gillmore; Ashutosh D Wechalekar; Thirusha Lane; Rene Williams; Taryn Youngstein; Philip N Hawkins; Sinisa Savic; Helen J Lachmann
Journal:  Blood       Date:  2017-12-28       Impact factor: 22.113

5.  Histopathologic characteristics of scleromyxedema: A study of a series of 34 cases.

Authors:  Franco Rongioletti; Giulia Merlo; Carla Carli; Bernard Cribier; Dieter Metze; Eduardo Calonje; Werner Kempf; Catherine M Stefanato; Eduardo Marinho; Jean Kanitakis
Journal:  J Am Acad Dermatol       Date:  2016-02-18       Impact factor: 11.527

6.  Paraproteinemic Keratopathy: The Expanding Diversity of Clinical and Pathologic Manifestations.

Authors:  Tatyana Milman; Andrew A Kao; David Chu; Matthew Gorski; Annie Steiner; Carrie Zaslow Simon; Carolyn Shih; Anthony J Aldave; Ralph C Eagle; Frederick A Jakobiec; Ira Udell
Journal:  Ophthalmology       Date:  2015-06-26       Impact factor: 12.079

7.  Clinical and Molecular Phenotyping in Scleromyxedema Pretreatment and Posttreatment With Intravenous Immunoglobulin.

Authors:  Christopher A Mecoli; C Conover Talbot; Andrea Fava; Christopher Cheadle; Francesco Boin; Fredrick M Wigley; Laura K Hummers
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-05-14       Impact factor: 4.794

8.  High-dose intravenous immunoglobulin therapy for systemic capillary leak syndrome (Clarkson disease).

Authors:  Zhihui Xie; Eunice C Chan; Lauren M Long; Celeste Nelson; Kirk M Druey
Journal:  Am J Med       Date:  2014-09-03       Impact factor: 4.965

9.  Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias.

Authors:  Christina Dicke; Sonja Schneppenheim; Katharina Holstein; Brigitte Spath; Carsten Bokemeyer; Rita Dittmer; Ulrich Budde; Florian Langer
Journal:  Ann Hematol       Date:  2016-04-04       Impact factor: 3.673

10.  DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis.

Authors:  Samih H Nasr; Julie A Vrana; Surendra Dasari; Frank Bridoux; Mary E Fidler; Sihem Kaaki; Nathalie Quellard; Alexia Rinsant; Jean Michel Goujon; Sanjeev Sethi; Fernando C Fervenza; Lynn D Cornell; Samar M Said; Ellen D McPhail; Loren P Herrera Hernandez; Joseph P Grande; Marie C Hogan; John C Lieske; Nelson Leung; Paul J Kurtin; Mariam P Alexander
Journal:  Kidney Int Rep       Date:  2017-08-08
View more
  6 in total

Review 1.  Immunoglobulin M Monoclonal Gammopathies of Clinical Significance.

Authors:  Louis-Pierre Girard; Cinnie Yentia Soekojo; Melissa Ooi; Wee Joo Chng; Sanjay de Mel
Journal:  Front Oncol       Date:  2022-06-09       Impact factor: 5.738

Review 2.  Diagnosis and management of monoclonal gammopathy of clinical significance.

Authors:  Hyungwoo Cho
Journal:  Blood Res       Date:  2022-04-30

3.  Corneal Densitometry and In Vivo Confocal Microscopy in Patients with Monoclonal Gammopathy-Analysis of 130 Eyes of 65 Subjects.

Authors:  Kitti Kormányos; Klaudia Kovács; Orsolya Németh; Gábor Tóth; Gábor László Sándor; Anita Csorba; Cecília Nóra Czakó; László Módis; Achim Langenbucher; Zoltán Zsolt Nagy; Gergely Varga; László Gopcsa; Gábor Mikala; Nóra Szentmáry
Journal:  J Clin Med       Date:  2022-03-26       Impact factor: 4.241

4.  Case Report: Monoclonal Gammopathies of Clinical Significance-Associated Myopathy: A Case-Based Review.

Authors:  Hongbin Yu; Du He; Qing Zhang; Bei Cao; Weiping Liu; Yu Wu
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

5.  Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors.

Authors:  Alessandro Gozzetti; Andrea Guarnieri; Elena Zamagni; Elena Zakharova; Daniel Coriu; Max Bittrich; Tomáš Pika; Natalia Tovar; Natalia Schutz; Sara Ciofini; Camila Peña; Serena Rocchi; Michael Rassner; Irit Avivi; Anna Waszczuk-Gajda; Saurabh Chhabra; Lidia Usnarska-Zubkiewicz; Verónica González-Calle; Maria-Victoria Mateos; Monica Bocchia; Flavia Bigi; Hannah Füllgraf; Bhavna Bhasin-Chhabra; Massimo Gentile; Julio Davila; David H Vesole; Michele Cavo; Bicky Thapa; Edvan Crusoe; Hermann Einsele; Wojciech Legiec; Grzegorz Charliński; Artur Jurczyszyn
Journal:  Am J Hematol       Date:  2022-04-20       Impact factor: 13.265

Review 6.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.